C G Schmidt|S Seeber - JoVE Visualize

Showing results (111-120 of 362) with videos related to

Pageof 37

Sort By:

Cytotechnology|November 13, 2008

Drug resistance and DNA repair in leukaemiaM R Müller, J Thomale, M F Rajewsky, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1990

Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumoursW Hoffmann, B Weidmann, F Migeod, et al.

Anti-Cancer Drugs|June 23, 1998

Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I studyU Klaassen, A Harstrick, D Strumberg, et al.

Deutsche Medizinische Wochenschrift (1946)|October 29, 1982

[Raynaud's phenomenon following combined cytostatic treatment of malignant testicular tumours]M E Scheulen, C G Schmidt

International Journal of Cancer|February 15, 1978

Chromosome findings in effusions from patients with Hodgkin's diseaseD K Hossfeld, C G Schmidt

Seminars in Oncology|March 4, 2000

Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinicU Vanhoefer, N Schleucher, U Klaassen, et al.

Journal of Cancer Research and Clinical Oncology|February 9, 2000

In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemiaJ K Schröder, S Kasimir-Bauer, S Seeber, et al.

Cancer Treatment Reviews|September 1, 1983

Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patientsM E Scheulen, N Niederle, K Bremer, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)U Vanhoefer, S Cao, A Harstrick, et al.

Annals of Hematology|October 10, 2002

Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapyP Bojko, D Pawloski, W Stellberg, et al.

Pageof 37

Showing results (111-120 of 362) with videos related to

Sort By:

Pageof 37

Cytotechnology|November 13, 2008

Drug resistance and DNA repair in leukaemiaM R Müller, J Thomale, M F Rajewsky, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1990

Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumoursW Hoffmann, B Weidmann, F Migeod, et al.

Anti-Cancer Drugs|June 23, 1998

Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I studyU Klaassen, A Harstrick, D Strumberg, et al.

Deutsche Medizinische Wochenschrift (1946)|October 29, 1982

[Raynaud's phenomenon following combined cytostatic treatment of malignant testicular tumours]M E Scheulen, C G Schmidt

International Journal of Cancer|February 15, 1978

Chromosome findings in effusions from patients with Hodgkin's diseaseD K Hossfeld, C G Schmidt

Seminars in Oncology|March 4, 2000

Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinicU Vanhoefer, N Schleucher, U Klaassen, et al.

Journal of Cancer Research and Clinical Oncology|February 9, 2000

In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemiaJ K Schröder, S Kasimir-Bauer, S Seeber, et al.

Cancer Treatment Reviews|September 1, 1983

Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patientsM E Scheulen, N Niederle, K Bremer, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)U Vanhoefer, S Cao, A Harstrick, et al.

Annals of Hematology|October 10, 2002

Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapyP Bojko, D Pawloski, W Stellberg, et al.

Pageof 37